Delgado P L, Moreno F A
Department of Psychiatry, University of Arizona Medical Center, Tucson, USA.
J Clin Psychiatry. 2000;61 Suppl 1:5-12.
This article reviews the role of norepinephrine (NE) and serotonin (5-HT) in depression and the therapeutic effects of antidepressant drugs from the perspective of human neurotransmitter depletion studies. The data reviewed suggest that both noradrenergic and serotonergic systems are involved in antidepressant action, but the specific impairment that underlies depression is unclear and is likely to vary among patients. Results from neurotransmitter depletion studies in depressed patients who have responded to treatment suggest that, while interactions between NE and 5-HT are likely, neither of these 2 neurotransmitter systems is the final common pathway for the therapeutic effect of antidepressant drugs. NE-selective antidepressant drugs appear to be primarily dependent on the availability of NE for their effects. Likewise, 5-HT-selective antidepressants appear to be primarily dependent on the availability of 5-HT for their effects. Antidepressants that cause effects on both noradrenergic and serotonergic systems-such as mirtazapine-may be dependent on the availability of both neurotransmitters for their effects. Neither 5-HT nor NE depletion induced clinical depression in healthy subjects or worsened depression in unmedicated symptomatic patients with major depression. This finding suggests that the cause of depression is more complex than just an alteration in the levels of 5-HT and/or NE. For some patients, depression may be more directly caused by dysfunction in brain areas or neuronal systems modulated by monoamine systems. We propose that antidepressant drugs may enhance neurotransmission in normal noradrenergic or serotonergic neurons and, through a time-dependent but as yet undiscovered process, restore function to brain areas modulated by monoamine neurons. Future research should focus on understanding the adaptive changes that follow enhancement of synaptic levels of monoamines in neuronal circuits of the frontal cortex, amygdala, and hippocampus. Research investigating the neurobiology of depression may be more informed if the focus is shifted to investigating areas of the brain modulated by monoamine systems rather than the monoamine systems themselves.
本文从人体神经递质耗竭研究的角度,综述了去甲肾上腺素(NE)和5-羟色胺(5-HT)在抑郁症中的作用以及抗抑郁药物的治疗效果。所综述的数据表明,去甲肾上腺素能和5-羟色胺能系统均参与抗抑郁作用,但导致抑郁症的具体损伤尚不清楚,且可能因患者而异。对治疗有反应的抑郁症患者进行神经递质耗竭研究的结果表明,虽然NE和5-HT之间可能存在相互作用,但这两种神经递质系统都不是抗抑郁药物治疗效果的最终共同途径。NE选择性抗抑郁药物的作用似乎主要取决于NE的可用性。同样,5-HT选择性抗抑郁药物的作用似乎主要取决于5-HT的可用性。对去甲肾上腺素能和5-羟色胺能系统均有作用的抗抑郁药物,如米氮平,其作用可能取决于这两种神经递质的可用性。5-HT或NE耗竭均未在健康受试者中诱发临床抑郁症,也未使未用药的重度抑郁症有症状患者的抑郁症恶化。这一发现表明,抑郁症的病因比单纯的5-HT和/或NE水平改变更为复杂。对于一些患者,抑郁症可能更直接地由单胺系统调节的脑区或神经元系统功能障碍引起。我们提出,抗抑郁药物可能增强正常去甲肾上腺素能或5-羟色胺能神经元的神经传递,并通过一个时间依赖性但尚未发现的过程,恢复由单胺神经元调节的脑区的功能。未来的研究应集中于了解额叶皮质、杏仁核和海马体神经元回路中单胺突触水平增强后随之发生的适应性变化。如果将研究重点从单胺系统本身转移到研究由单胺系统调节的脑区,那么对抑郁症神经生物学的研究可能会更有成效。